Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Alapure BV, Praveen MR, Gajjar DU, Vasavada AR, Parmar TJ, Arora AI
The results of this study demonstrated that switching to injectable semaglutide therapy was more effective than continuous dulaglutide therapy in reducing an oxidative stress marker, d-ROMs, and glucose variability in patients with T2DM, whereas continuous dulaglutide therapy demonstrated higher treatment satisfaction than its counterpart
Refund Policy Per Company Terms: According to the published refund policy, customers may return products within 30 days of delivery if they are unsatisfied, provided the products are returned in their original condition
Major cardiovascular outcome trials include: LEADER trial (liraglutide): Demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk SUSTAIN-6 (semaglutide): Showed reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke REWIND (dulaglutide): Confirmed cardiovascular benefits across a broad patient population SELECT trial (semaglutide): Showed reduced MACE in people with obesity without diabetes, though this evidence is not yet fully incorporated into UK labelling [17] These trials consistently found that the modest heart rate increases observed did not translate into adverse cardiovascular outcomes
doi: 10.1038/ki.2014.246 44 Mori ITI
